Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 7,256 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Endometrial Cancer
Interventions: Carboplatin and Paclitaxel, Radiation Therapy; Drug · Radiation
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Marywood, Illinois

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia
Interventions: Clofarabine; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: total marrow irradiation, melphalan, peripheral blood stem cell transplantation, filgrastim, fluorescence in situ hybridization, cytogenetic analysis, cyclophosphamide, autologous-autologous tandem hematopoietic stem cell transplantation, lenalidomide; Radiation · Drug · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Up to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2019
U.S. locations: 1
States / cities: Duarte, California

Conditions: Myelofibrosis
Interventions: Imetelstat, Best Available Therapy (BAT); Drug
Lead sponsor: Geron Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • New Haven, Connecticut + 9 more

Conditions: Nearsightedness, Astigmatism
Interventions: LASIK; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hypertension, High Blood Pressure
Interventions: Losartan, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma, Gastric Adenocarcinoma, Malignant Mesothelioma (MM), Von Hippel Lindau, Bladder Cancer, Bladder Urothelial Carcinoma
Interventions: 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors; Diagnostic Test
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more

Conditions: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions: HDMP + rituximab as a means of debulking prior to initiating venetoclax.; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pancreatic Ductal Carcinoma
Interventions: Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Placebo, nab-Paclitaxel, Gemcitabine; Other · Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 64
States / cities: Mobile, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 52 more

Conditions: Hypertension, Diabetes Mellitis
Interventions: Medical Practice Improvement, Patient Education and Support, Combination Intervention to Include Medical Practice Improvement and Patient Education and Support; Behavioral · Other
Lead sponsor: Harvard Medical School (HMS and HSDM); Other
Eligibility: 18 Years and older
Enrollment: 1,204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Failure to Thrive
Interventions: Training; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Eating Disorders in Adolescence
Interventions: mind. body. voice; Behavioral
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: Female only
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: American Medical Association; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma
Interventions: Phased Variant Enrichment and Detection Sequencing (PhasED-seq), Standard of Care Treatment, De-escalated Treatment; Device · Other
Lead sponsor: Hua-Jay J Cherng, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions: Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy; Radiation · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cystic Fibrosis
Interventions: High frequency chest wall oscillator; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 19 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low, Blood Glucose, High
Interventions: Discharge Order Set (DOS), Enhanced Standard Care (ESC); Other
Lead sponsor: Ohio State University; Other
Eligibility: 25 Years to 75 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 32
States / cities: Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 28 more

Conditions: Hematological Malignancies
Interventions: Regimen A, Regimen B, Regimen C; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 1 Year to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hemodynamic Measure, Cognitive Performance in Healthy Volunteers
Interventions: Maltodextrin (Placebo), Low dose theacrine, Medium dose theacrine, High dose theacrine; Dietary Supplement
Lead sponsor: Titch Madzima; Other
Eligibility: 18 Years to 40 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Elon, North Carolina

Conditions: COPD, Healthy Volunteers
Interventions: Airvo 3 with respiratory rate algorithm; Device
Lead sponsor: Fisher and Paykel Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Obesity
Interventions: Active Video Game Play, Passive Video Game Play; Behavioral
Lead sponsor: Brigham Young University; Other
Eligibility: 12 Years to 15 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Provo, Utah

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: psychosocial assessment and care; Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2005
U.S. locations: 26
States / cities: Sacramento, California • Gainesville, Florida • Miami, Florida + 23 more

Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, cyclosporine, mycophenolate mofetil, bortezomib, lenalidomide, laboratory biomarker analysis; Drug · Radiation · Procedure + 1 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer

PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

High Resolution Wavefront-guided vs. Wavefront Optimized LASIK

N-of-1 Trials for Blood Pressure Medications in Adults

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Community Partnership to Examine Racial and Ethnic Differences in Health Care for Hypertension and Diabetes

Palliative Care Population Management Project for Integrated Care Management Program for High-Risk Patients

The Peer-Delivered "Mind. Body. Voice." Program for High School Women (Mbv) - Remote

Improving Health Outcomes: Blood Pressure

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Comparison of Airway Clearance Efficacy of Two High Frequency Chest Wall Oscillation (HFCWO) Devices in Cystic Fibrosis

Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin

A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)

Assessing the Impact of High Theacrine Doses on Hemodynamic Measures

Airvo 3 Respiratory Rate Validation Study

Response Inhibition to High Calorie Food Cues Among Adolescents Following Active and Sedentary Video Game Play

Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma